The shingles shot prevents the reactivation of the varicella-zoster virus, which causes shingles-a painful rash and nerve condition that affects about 1 in 3 adults in the U.S. It reduces the risk of developing shingles by 90% and lowers the chance of postherpetic neuralgia, a complication that causes chronic pain lasting months or years.
Shingles occurs when the same virus that causes chickenpox reactivates later in life. After a person recovers from chickenpox, the virus remains dormant in nerve tissue. As immunity weakens with age, the virus can reactivate and travel along nerves, causing a painful rash that typically appears on one side of the body or face. The shingles shot boosts the immune system's ability to recognize and suppress the virus before it causes symptoms.
Two vaccines are available: Zostavax, a live attenuated vaccine, and Shingrix, a recombinant subunit vaccine. Shingrix is preferred because it provides stronger and longer-lasting protection. The CDC recommends Shingrix for healthy adults aged 50 and older, regardless of whether they remember having had chickenpox.
The shingles shot trains the immune system to respond quickly if the varicella-zoster virus reactivates. Shingrix contains a piece of the virus-the glycoprotein E-and an adjuvant that enhances the immune response. This combination triggers a strong, targeted reaction without using live virus, reducing the risk of side effects compared to older vaccines.
After vaccination, the body produces antibodies and memory T cells specific to the virus. These cells remain in circulation and can rapidly deploy if the virus attempts to reactivate. Clinical trials showed that Shingrix reduced shingles incidence by 97% in people aged 50-69 and 91% in those 70 and older.
Protection lasts at least 10 years. A study published in The New England Journal of Medicine tracked participants for over 7 years and found sustained high antibody levels, indicating durable immunity. Even among immunocompromised individuals, Shingrix showed significant efficacy, though timing relative to treatment may vary.
There are two FDA-approved shingles vaccines. They differ in composition, effectiveness, and recommended use.
| Vaccine | Type | Effectiveness Against Shingles | Recommended Age | Dosing Schedule |
|---|---|---|---|---|
| Zostavax | Live attenuated | 51% reduction | 60+ | One dose |
| Shingrix | Recombinant subunit | 97% reduction (ages 50-69) | 50+ | Two doses, 2-6 months apart |
Shingrix is now the standard of care. Zostavax was withdrawn from the U.S. market in 2020 due to lower efficacy and higher risk of adverse events, including rare cases of disseminated zoster in recipients. Shingrix has no live virus, making it safe for most people, including those with mild immune suppression.
People who received Zostavax in the past should still get Shingrix if they are eligible. The CDC states that even if someone previously got Zostavax, they should receive Shingrix for better protection. No minimum interval is required between the two vaccines.
The Centers for Disease Control and Prevention (CDC) recommends Shingrix for all adults aged 50 and older, even if they've had shingles before. About 1 in 10 people who've had shingles will experience a recurrence, and the vaccine reduces that risk.
Adults aged 70 and older should get Shingrix even if they're unsure whether they had chickenpox. Over 99% of Americans born before 1980 have had chickenpox, and the virus remains latent in nearly all of them. The vaccine doesn't require a prior history of chickenpox to be effective.
I received the shingles shot during a routine check-up at age 52. My doctor noted that my immune response to the vaccine was strong, confirmed by blood tests showing high antibody titers. I've had no symptoms since, and my primary care provider emphasized that the shot is not just for prevention-it also reduces severity if breakthrough infection occurs.
Many assume the shingles shot is only for people who've had chickenpox. That's incorrect. The virus is widespread-over 95% of U.S. adults aged 50+ have been exposed. The vaccine targets the dormant virus, not the initial infection.
Another myth is that shingles only affects older adults. While risk increases sharply after age 50, younger adults can develop shingles, especially if immunosuppressed. Cases in people under 50 are rare but documented, particularly in those with HIV or undergoing chemotherapy.
Some believe the shot causes shingles. This is false. Shingrix uses no live virus. It cannot cause shingles. Side effects like soreness at the injection site, fatigue, or muscle pain occur in about 50% of recipients but resolve within 1-2 days. Severe allergic reactions are extremely rare-fewer than 1 in 100,000 doses.
Without vaccination, the risk of shingles rises with age. By age 80, about 1 in 5 people will develop shingles. The average episode lasts 3-5 weeks. Postherpetic neuralgia affects 10-15% of patients and can persist for years, leading to chronic pain, sleep disruption, and depression.
A 2021 study in JAMA Internal Medicine found that unvaccinated adults were twice as likely to be hospitalized for shingles-related complications compared to vaccinated peers. The cost of treating shingles, including medications and lost work time, averages $1,500 per case in the U.S., with higher costs for severe outcomes.
Even if you've had shingles, getting the shot reduces your chance of recurrence. One study showed a 67% reduction in reinfection among those who received Shingrix after a prior episode.
The shingles shot is a critical tool for preventing a painful and potentially debilitating condition. It works by boosting immunity against the varicella-zoster virus before it reactivates. Getting the shingles shot is not optional for adults 50 and older-it's a proven way to avoid long-term suffering and healthcare burden.